Even though our study showed the possibility of HDAC inhibitor for patients in the high-risk group, inhibition of NPM1 based on not only the direct effect on NPM1 itself but also indirect effects including sensitizing cancer cells would be the promising treatment strategy in the future [38]. This evidence concerns the gene HDAC9 and cancer.